Pricing Log in Create free account
Saturday 17 October 2026 Export LFCR’s income statement to Excel — free account

Lifecore Biomedical, Inc.

LFCR Healthcare Drug Manufacturers Specialty & Generic

In the quarter to June 2026, revenue fell 6.25%, EPS fell 216.7%, free cash flow fell 117.0% and total debt rose 15.3%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

6.38 0.06 −0.93%
Market cap
$244.1M
P/E
0.0×
Fwd P/E
−5.4×
Dividend yield
—
F-score
3/9
Altman Z
0.12
Beneish M
−3.15
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 8.80%

Capital & Financial Ratios $m

Market Cap 244.12
Revenue 119.58
Net Income (21.14)
Free Cash Flow (5.06)
Net Debt 167.78
Current Ratio 3.87 (at or above 1.5: strong)
Debt/Equity 11.50 (above 2: weak)
P/E ratio 0.00
Fwd P/E (5.39) (negative: loss-making)
P/S ratio 2.00
P/B ratio 0.00
Past 5Y EPS Growth —
This Y EPS Growth 42.91% (at or above 15%: strong)
Next Y EPS Growth 40.69% (at or above 15%: strong)
Next Y revenue growth (6.03%) (below 0%: weak)
Next 5Y EPS Growth 10.00%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 3.4×, against a ten-year median of 2.5×; over the ten years it ranged from −6.1× in 2021 to 68.9× in 2021.
P/S against its own 10 years 68.28%
10-year low 10-year high
EV/Sales against its own 10 years 73.84%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2018 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 19 8 8 17
Receivables 29 27 29 30
Inventory 41 40 32 25
Other 5 4 7 8
94 81 86 84
2023 2024 2025 Q'26
Payables 22 16 8 8
ST’ Debt 1 1 — —
Other — — — —
39 39 30 22

Compound Annual Growth %

10y 5y 3y
Sales (13.34%) (4.24%) 5.02%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (14.23%) (27.14%) (18.56%)

Revenue $m

Aug Nov Feb May Year
’26 31 — — — —
’25 25 33 35 26 129
’24 25 30 36 38 128
’23 24 22 27 31 103
’22 42 43 37 (11) 111
’21 136 131 45 (210) 101
’20 139 143 153 (274) 160
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Aug Nov Feb May Year
’26 2 — — — —
’25 (1) (6) (6) 5 0
’24 (8) 1 (8) 9 0
’23 (1) (2) (15) (2) (17)
’22 1 (5) (22) (1) (23)
’21 17 1 11 6 16
’20 (5) (9) (4) (13) (17)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Aug Nov Feb May Year
’26 0 — — — —
’25 (4) (9) (10) 3 (7)
’24 (13) (3) (24) 6 (18)
’23 (4) (3) (29) (9) (39)
’22 (6) (10) (39) (12) (51)
’21 17 7 12 (8) 4
’20 (15) (16) (24) (17) (41)
Fiscal quarters ending in the months shown.

EPS $

Aug Nov Feb May Year
’26 — — — — —
’25 (0.53) (0.19) (0.40) (0.06) (1.11)
’24 (0.35) 0.39 0.43 (0.20) 0.33
’23 (0.37) (0.43) (1.20) (1.19) (3.32)
’22 (0.32) (1.30) (0.44) (1.24) (3.96)
’21 (0.38) (0.45) (0.19) (0.10) (1.10)
’20 (0.16) (0.23) (0.39) (0.52) (1.31)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to May

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 9.48 11.20 11.45 9.00 7.48 7.65 6.23 1.52 3.68 4.76

Analyst estimates 2026–2028

Powerpack
High 15.50 14.95 15.60 13.24 11.89 12.88 12.04 11.46 8.90 8.85
People
People Employees 552 670 710 736 796 905 689 459 524 406
Revenue/emp, $m 0.86 0.70 0.74 0.76 0.20 0.11 0.16 0.22 0.24 0.32
Income, $m
Income, $m Revenue 477 470 524 558 160 101 111 103 128 129
Gross margin, % 14.00 16.86 14.94 14.53 24.61 38.60 35.11 27.10 32.63 31.27
EBT (20) 14 16 4 (31) (30) (21) (64) 10 (39)
EBT margin, % (4.13) 3.02 3.13 0.65 (19.15) (29.53) (18.59) (61.90) 7.42 (30.01)
Net income (11) 11 25 0 (38) (32) (117) (100) 12 (39)
Depreciation 9 11 12 15 32 20 96 14 8 8
Per share, $
Per share, $ Revenue 17.63 17.22 19.04 19.66 5.49 3.44 3.78 3.45 4.21 3.70
Earnings (0.42) 0.39 0.91 0.01 (1.31) (1.10) (3.96) (3.32) 0.39 (1.11)
Cash flow 0.77 1.09 0.72 0.56 (0.58) 0.56 (0.77) (0.58) 0.01 (0.01)
Capex (1.46) (0.84) (1.22) (1.57) (0.83) (0.42) (0.98) (0.72) (0.60) (0.18)
Free cash flow (0.70) 0.25 (0.50) (1.00) (1.42) 0.14 (1.74) (1.30) (0.60) (0.19)
Book value 7.85 8.36 9.17 9.53 7.92 6.92 2.98 1.17 1.77 1.36
Shares, m 27 27 28 28 29 29 29 30 30 35
Valuation, ×
Valuation, × P/E 0.00 35.77 15.62 781.10 0.00 0.00 0.00 0.00 14.75 0.00
P/S 0.66 0.81 0.74 0.50 1.97 3.38 2.52 2.38 1.39 1.85
P/B 1.47 1.67 1.54 1.04 1.37 1.68 3.09 0.00 15.73 179.05
EV/Sales 0.76 0.92 0.87 0.77 3.16 5.29 3.84 3.80 2.49 2.97
EV/FCF (11.52) 55.76 (27.38) (10.16) (7.01) 19.00 (6.32) (8.46) (9.26) (30.80)
Cash, $m
Cash, $m Operating cash flow 21 30 20 16 (17) 16 (23) (17) 0 0
Capex (40) (23) (33) (44) (24) (12) (29) (21) (18) (6)
Free cash flow (19) 7 (14) (28) (41) 4 (51) (39) (18) (7)
Balance, $m
Balance, $m Working capital 30 30 9 (4) (7) 46 (60) 55 42 55
Total debt 61 54 73 149 190 194 148 167 150 152
Net debt 51 48 70 148 190 193 147 147 141 144
Shareholders’ equity 212 228 253 270 231 203 88 35 54 47
Returns, %
Returns, % ROA (3.38) 3.02 6.51 0.09 (7.20) (6.19) (30.02) (37.70) 4.73 (17.98)
ROIC (4.89) 3.32 2.63 0.82 (3.84) (1.39) (3.14) (7.46) (2.83) (5.64)
ROE (5.38) 4.81 10.33 0.16 (15.24) (14.89) (80.32) (238.21) 339.11 (701.27)
Negative figures in brackets.

All 10 years →

Fiscal years to May 2025 · latest quarter Jun 2026

Charts ten years each

Lifecore Biomedical, Inc. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
TKNO Alpha Teknova, Inc. $408.0M — (loss-making) — (loss-making) +18.45% (above 0%: growing) n/m +74.18% (above 0%: growing) 40.09% (23.72%) Compare
EBS Emergent Biosolutions Inc. $368.1M — (loss-making) — (loss-making) +66.29% (above 0%: growing) n/m −47.68% (below 0%: shrinking) 58.56% (53.39%) Compare
CGC Canopy Growth Corporation $311.2M — (loss-making) — (loss-making) +12.41% (above 0%: growing) n/m −117.60% (below 0%: shrinking) 27.40% (27.24%) Compare
ANIK Anika Therapeutics Inc. $276.9M — (loss-making) — (loss-making) +15.56% (above 0%: growing) n/m +61.58% (above 0%: growing) 65.15% 9.06% Compare
ACB Aurora Cannabis Inc. $265.8M — (loss-making) — (loss-making) −31.15% (below 0%: shrinking) n/m −293.56% (below 0%: shrinking) 52.73% (12.92%) Compare
BIOA BioAge Labs, Inc. $245.6M — (loss-making) — (loss-making) +1.62% (above 0%: growing) n/m +2.68% (above 0%: growing) 100.00% (1,196.78%) Compare
LFCR Lifecore Biomedical, Inc. $244.1M — (loss-making) — (loss-making) −6.25% (below 0%: shrinking) n/m −117.03% (below 0%: shrinking) 35.34% 7.51%
SIGA Siga Technologies Inc. $229.2M — (loss-making) 28.7× −49.45% (below 0%: shrinking) −66.00% (below 0%: shrinking) −75.95% (below 0%: shrinking) 57.17% 33.91% Compare
AKBA Akebia Therapeutics, Inc. $192.7M — (loss-making) — (loss-making) −21.36% (below 0%: shrinking) n/m −88.99% (below 0%: shrinking) 78.78% (12.88%) Compare
Median of peers $271.4M — — +7.02% — −61.81% 57.87% (18.32%)

All 86 Drug Manufacturers Specialty & Generic stocks →

Lifecore Biomedical, Inc. (LFCR) key facts

  • Lifecore Biomedical, Inc. (LFCR) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, LFCR traded at $6.38, a market capitalization of $244.1 million.
  • Return on equity was −701.3% and debt-to-equity 11.50.
  • Its Piotroski F-score is 3 out of 9 and its Altman Z-score is 0.12 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Lifecore Biomedical, Inc. (LFCR) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/LFCR · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com